860 related articles for article (PubMed ID: 26387133)
1. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
4. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
6. An overview of triple-negative breast cancer.
Kumar P; Aggarwal R
Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
[TBL] [Abstract][Full Text] [Related]
7. An overview of triple negative breast cancer for surgical oncologists.
Sharma S; Barry M; Gallagher DJ; Kell M; Sacchini V
Surg Oncol; 2015 Sep; 24(3):276-83. PubMed ID: 26092709
[TBL] [Abstract][Full Text] [Related]
8. Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy.
Braicu C; Chiorean R; Irimie A; Chira S; Tomuleasa C; Neagoe E; Paradiso A; Achimas-Cadariu P; Lazar V; Berindan-Neagoe I
Expert Rev Mol Med; 2016 Nov; 18():e18. PubMed ID: 27817751
[TBL] [Abstract][Full Text] [Related]
9. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.
Safarpour D; Tavassoli FA
Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
Yam C; Mani SA; Moulder SL
Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
[TBL] [Abstract][Full Text] [Related]
11. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
[TBL] [Abstract][Full Text] [Related]
12. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
13. S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
Maierthaler M; Kriegsmann M; Peng C; Jauch S; Szabo A; Wallwiener M; Rom J; Sohn C; Schneeweiss A; Sinn HP; Yang R; Burwinkel B
Exp Mol Pathol; 2015 Aug; 99(1):180-7. PubMed ID: 26112095
[TBL] [Abstract][Full Text] [Related]
14. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
[TBL] [Abstract][Full Text] [Related]
16. MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer.
Mathe A; Scott RJ; Avery-Kiejda KA
Int J Mol Sci; 2015 Nov; 16(12):28347-76. PubMed ID: 26633365
[TBL] [Abstract][Full Text] [Related]
17. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
18. New targets for triple-negative breast cancer.
Herold CI; Anders CK
Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
[TBL] [Abstract][Full Text] [Related]
19. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
Astvatsaturyan K; Yue Y; Walts AE; Bose S
PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]